Ocular Therapeutix to disclose interim Phase 1 data for OTX-TKI at AAO 2022

OCULAR THERAPEUTIX, INC

Company posted slides from Eyecelerator @ AAO 2022 Retina Showcase on its website.
Interim data from U.S. Phase 1 trial of OTX-TKI to be presented at AAO Retina Subspecialty Day on Sept 30, 2022.
Presentations by Dr. Peter Kaiser (Chief Medical Advisor, Retina) and Dr. Dilsher Dhoot.
No specific results or data included in the 8-K filing; materials to be posted on investors section.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.